Abstract
Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.